

**Date: April 29, 2026**

To,  
National Stock Exchange of India Limited  
BSE Limited  
Symbol: NSE: GRANULES: BSE: 532482

Dear Sir,

**Sub: Press Release to the Analysts/Investors**

We refer to the audited financial results for the fourth quarter and financial year ended on March 31, 2026, submitted to you today i.e., on April 29, 2026. We are now enclosing the press release to the Analysts/Investors.

This is pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the above information on record.

**For GRANULES INDIA LIMITED**

**CHAITANYA TUMMALA  
(COMPANY SECRETARY &  
COMPLIANCE OFFICER)**



**REGISTERED OFFICE**

**Granules India Limited**  
CIN: L24110TG1991PLC012471  
15<sup>th</sup> Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad – 500084, Telangana, India  
Contact Us: Tel: +91 40 69043500 | Fax: +91-40-23115145 | mail@granulesindia.com

[www.granulesindia.com](http://www.granulesindia.com)

Press Release

for Immediate Release

**Q4FY26 Revenue from operations at INR 14,706 Mn up 23% YoY, EBITDA at INR 3,521 Mn up 40% YoY, PBT before Exceptional Item at INR 2,464 Mn up 48% YoY, PAT at INR 2,016 Mn up 33% YoY.**

**Hyderabad, India, April 29, 2026:** Granules India Ltd., a vertically integrated pharmaceutical company, today announced its financial results for the quarter and financial year ended March 31, 2026.

**Financial Summary (All numbers in INR Mn)**

QUARTERLY CONSOLIDATED FINANCIALS	Q4FY26	Q3FY26	Growth (QoQ)	Q4FY25	Growth (YoY)
Revenue from Operations	14,706	13,879	6%	11,974	23%
EBITDA	3,521	3,081	14%	2,524	40%
EBITDA %	24%	22%		21%	
PBT Before Exceptional Item	2,464	2,022	22%	1,668	48%
Exceptional Item / (Income)	(159)			(308)	
PAT	2,016	1,502	34%	1,520	33%
PAT %	14%	11%		13%	

ANNUAL CONSOLIDATED FINANCIALS	FY26	FY25	Growth (YoY)
Revenue from Operations	53,656	44,816	20%
EBITDA	11,851	9,452	25%
EBITDA %	22%	21%	
PBT Before Exceptional Item	7,950	6,294	26%
Exceptional Item / (Income)	100	(308)	
PAT	5,950	5,015	19%
Net Profit Margin	11%	11%	

**Financial and Business Summary for Q4FY26**

- Revenue from Operations of Q4FY26 stood at INR 14,706 Mn, a growth of 23% YoY, Revenue share from the North America is 72% in Q4 FY26 as compared to 79% in Q4 FY25 and from the Europe is 17% in Q4FY26 as compared to 8% in Q4FY25.
- Finished dosages (FD), Active Pharmaceuticals Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Peptide/CDMO contribute 73%, 13%, 9% and 5% of revenue from operations respectively for Q4FY26.
- ROCE improved to 17.6% in FY26 from 16.6% in FY25.
- Net debt stood at INR 4,021 Mn, a reduction of INR 3,040 Mn from Q4FY25 and Net debt to EBITDA at 0.34x

**Commenting on the results, Dr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said,** “We delivered a strong performance in Q4FY26, driven by continued portfolio expansion, disciplined execution, and steady progress across regulatory, compliance, and sustainability initiatives. The quarter reflects improving earnings quality and sustained advancement in Complex Generics and the Peptides CDMO platform”.

### **About Granules India Ltd. (BSE: 532482, NSE: GRANULES)**

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs) and Peptides CDMO. Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US, and UK. The Company has 10 manufacturing facilities out of which 7 are in India, 2 in the USA and 1 in Switzerland and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL.

### **Safe Harbor**

*This document includes certain forward-looking statements. These statements are based on management's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological, and/or regulatory factors. Granules India Ltd., its directors, and any of the affiliates or employees are under no obligation to and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.*

<b>Contacts:</b>	
<b>Granules IR Desk</b> investorrelations@granulesindia.com	<b>Chaitanya Tummala</b> Company Secretary chaitanya.tummala@granulesindia.com